Citeline recently released a report looking at the current volume of - or lack of - the number of Type II Diabetes. This disease is rising in numbers across today's youth population. Once thought of adult-onset diabetes, no one knows why it's spreading to the youth. Some factors considered to be causing the increase include obesity, sedentary lifestyles and possibly exposure to diabetes in-utero.
This report, Pediatric Type 2 Diabetes Trials: Are We Content with the Bare Minimum?, takes an in-depth look at how the Pharma industry is responding and conducting clinical trials. According to their records, Citeline found that there are 57 trials enrolling pediatric patients. Of the trials, 43 were single sponsors and 14 were collaborative. Pediatric Research Equity Act (PREA) is believed to be the reason why 58% of these trials as post marketing were taking place.
Download the full report to find out more about which Pharma companies are conducing these trials, where they are taking place and more.
Do you think that due to the increase in pediatric Type II Diabetes cases will result in more clinical trials to find a treatment? Or will companies continue to only what is required by the FDA?
The Partnerships in Clinical Trials Blog focuses on optimization intelligence, regulatory trends and globalization strategies for both sponsors and CROs. It is supported by a number of industry events.
Would you like to guest blog on our site? Or send us feedback? Send an email to email@example.com.